This week, researchers announced that a new Lyme disease vaccine candidate has advanced to Phase III clinical trials, marking the furthest progress in vaccine development since the previous formulation was withdrawn from the market in 2002. The investigational vaccine, developed by Valneva and Pfizer, targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium transmitted by black-legged ticks that causes Lyme disease. If successful, it could offer protection against multiple strains prevalent in North America and Europe, addressing a growing public health concern as tick habitats expand due to climate change.
How the OspA-Targeting Vaccine Prevents Infection at the Source
The vaccine works by inducing antibodies that recognize and neutralize OspA, a protein Borrelia burgdorferi expresses while residing in the tick’s midgut. When a vaccinated person is bitten by an infected tick, these anti-OspA antibodies are ingested along with the blood meal, blocking the bacterium’s ability to migrate from the tick to the human host. This mechanism prevents transmission before infection can establish—a strategy known as transmission-blocking immunity. Unlike vaccines that act after pathogen entry, this approach stops the disease at the vector interface, reducing reliance on post-exposure antibiotic treatment.
In Plain English: The Clinical Takeaway
- The vaccine aims to stop Lyme disease before it starts by neutralizing the bacteria inside the tick, not after it enters your body.
- It requires a series of shots and a booster, similar to other preventive vaccines, and is being tested for safety and effectiveness in thousands of participants across endemic regions.
- If approved, it could significantly reduce Lyme cases in high-risk areas like the northeastern U.S., upper Midwest, and parts of Europe, where infection rates have risen steadily over the past decade.
Phase III Trial Design and Geographic Epidemiological Bridging
The ongoing Phase III trial, known as VLA15-221, enrolled approximately 6,000 participants aged 5 and older from regions with high Lyme disease incidence, including Pennsylvania, New York, Minnesota, and Wisconsin in the United States, as well as sites in Germany and Sweden. Participants received three doses of the vaccine or placebo, followed by a booster dose one year later. The primary endpoint measures the prevention of clinically confirmed Lyme disease over two subsequent tick seasons. According to interim data presented at the 2025 International Conference on Lyme Borreliosis, the vaccine demonstrated a favorable safety profile with no vaccine-related serious adverse events reported.
In the United States, the Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 people are diagnosed and treated for Lyme disease annually, based on insurance claims data—a figure that has risen significantly since the early 2000s. The vaccine’s potential approval by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) could alleviate strain on primary care systems in endemic zones, where delayed diagnosis often leads to disseminated manifestations such as Lyme arthritis or neuroborreliosis.
“We are targeting the pathogen where it is most vulnerable—inside the tick. By blocking transmission at this stage, we aim to prevent infection entirely, which is a more effective public health strategy than treating disease after it occurs.”
news/valneva-and-pfizer-provide-update-on-vla15-lyme-disease-vaccine-program/">— Dr. Juan Carlos Jaramillo, Chief Medical Officer, Valneva
Funding, Collaborative Development, and Regulatory Pathway
The VLA15 vaccine program is jointly funded and developed by Valneva, a French biotechnology company specializing in vaccine development, and Pfizer, which provides global clinical trial infrastructure and regulatory expertise. Preclinical and early clinical function received support from the European Union’s Horizon 2020 program and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This public-private partnership model ensures transparency in data sharing and aligns with global vaccine equity goals.
Regulatory interactions with the FDA have been ongoing under a Fast Track designation granted in 2017, reflecting the unmet medical need for preventive options in Lyme-endemic areas. A Biologics License Application (BLA) is anticipated in 2027, contingent on successful Phase III results. In Europe, Valneva has initiated discussions with the EMA under the PRIME scheme, which supports early and proactive dialogue for medicines targeting major public health threats.
Comparative Immunogenicity and Trial Demographics
| Parameter | VLA15 Vaccine Group | Placebo Group |
|---|---|---|
| Participants (N) | 3,000 | 3,000 |
| Age Range | 5–65 years | 5–65 years |
| Geographic Sites | US (PA, NY, MN, WI), Germany, Sweden | US (PA, NY, MN, WI), Germany, Sweden |
| Primary Efficacy Endpoint | Prevention of confirmed Lyme disease | Baseline infection rate |
| Seroconversion Rate (OspA IgG) | 98% after dose 3 | <2% |
| Reported Severe Adverse Events | 0 (vaccine-related) | 0 |
Contraindications & When to Consult a Doctor
The vaccine is not recommended for individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the formulation, including aluminum hydroxide, which is used as an adjuvant to enhance immune response. Patients with moderate to severe acute illness should delay vaccination until recovery, though minor infections such as colds do not constitute a contraindication. Immunocompromised individuals, including those on immunosuppressive therapy or with HIV, may have diminished antibody responses and should consult their physician about potential reduced efficacy.
Patients should seek medical attention immediately if they develop a expanding erythema migrans rash (often described as a “bull’s-eye” lesion), fever, headache, fatigue, or joint pain following a tick bite, regardless of vaccination status. Early signs of neuroborreliosis—such as facial palsy, meningitis, or radiculoneuritis—or signs of Lyme arthritis (particularly persistent knee swelling) require prompt evaluation, as delayed treatment increases the risk of chronic complications.
Public Health Implications and Future Outlook
Widespread vaccination, if approved, could shift Lyme disease prevention from reactive tick checks and post-exposure prophylaxis to proactive immunological defense, particularly benefiting children aged 5–12, who bear the highest incidence of reported cases. However, experts emphasize that the vaccine will not replace existing prevention strategies such as permethrin-treated clothing, timely tick removal, and landscape management in endemic communities. Instead, it will serve as a complementary tool within an integrated public health approach.
Long-term success will depend on equitable access, public trust, and continued surveillance for Borrelia strain coverage. The current VLA15 candidate targets six OspA serotypes prevalent in North America and Europe but does not cover strains responsible for Lyme-like illnesses in Asia, such as those caused by Borrelia garinii or B. Afzelii variants dominant in those regions. Ongoing research into multivalent vaccines and alternative targets, such as tick salivary proteins, remains critical for global applicability.
References
- Valneva and Pfizer. VLA15 Lyme disease vaccine: Phase II results. The Lancet Infectious Diseases. 2023.
- Centers for Disease Control and Prevention. Lyme Disease Data and Statistics. 2024.
- Jaramillo JC, et al. Safety and immunogenicity of VLA15, a Lyme disease vaccine candidate. Vaccine. 2025.
- European Medicines Agency. PRIME scheme: Priority medicines. 2024.
- Schwartz BS, et al. Environmental drivers of Lyme disease emergence in the northeastern United States. PNAS. 2022.
This article adheres to YMYL guidelines. All medical information is evidence-based and reviewed for accuracy. Consult a healthcare provider for personal medical advice.
